Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma
Ganesan Ramamoorthi(Moffitt Cancer Center), Brian J. Czerniecki(Moffitt Cancer Center), Krithika N. Kodumudi(Moffitt Cancer Center), Corey Gallen(Moffitt Cancer Center), Payal Grover(University of Pennsylvania), Amrita Basu(University of Calcutta), Hyo S. Han(Moffitt Cancer Center), Gary K. Koski(Kent State University), Hongtao Zhang(Chinese Academy of Sciences), Mark I. Greene(University of Pennsylvania), Ricardo Costa(Moffitt Cancer Center), Colin Snyder(Moffitt Cancer Center), Doris Wiener(Moffitt Cancer Center)
Cited by 26
Related Papers
National Survey of Drug-Resistant Tuberculosis in China
|New England Journal of Medicine|2012|649
ErbB receptors: from oncogenes to targeted cancer therapies
|Journal of Clinical Investigation|2007|578
Advances in clinical immunotherapy for gastric cancer
|Biochimica et Biophysica Acta (BBA) - Reviews on Cancer|2021|435